Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 8/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.44 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20528853 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2ALDH1A1FOLH1NOD1ALB | |
| SCHEMBL19069648 | 0.88 | ALB (0.56) | SMN1; SMN2ALDH1A1FOLH1NOD1ALB | |
| SCHEMBL16790769 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2ALDH1A1FOLH1NOD1ALB | |
| SCHEMBL20528860 | 0.82 | FOLH1 (0.49) | FOLH1NOD1ALB | |
| SCHEMBL20528861 | 0.82 | FOLH1 (0.49) | FOLH1NOD1ALB | |
| SCHEMBL20477195 | 0.82 | FOLH1 (0.58) | FOLH1NOD1GNPAT | |
| SCHEMBL11708581 | 0.82 | FOLH1 (0.58) | FOLH1NOD1GNPAT | |
| SCHEMBL5215821 | 0.82 | FOLH1 (0.58) | FOLH1NOD1GNPAT | |
| SCHEMBL22551144 | 0.81 | NOD1 (0.64) | FOLH1NOD1EPHX2 | |
| SCHEMBL14217259 | 0.81 | MEN1 (0.59) | FOLH1NOD1ALBEPHX2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | NOVO NORDISK A/S (DK) | 2022-10-18 | — | — | US | disclosed |
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | NOVO NORDISK A/S (DK) | 2020-08-20 | — | — | US | disclosed |
| EP-3606560-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | Novo Nordisk A/S (DK) | 2020-02-12 | — | — | EP | disclosed |
| WO-2018185131-A2 | OLIGOMER EXTENDED INSULIN-FC CONJUGATES | NOVO NORDISK A/S (DK) | 2018-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261595-A1 | Oligomer Extended Insulin-FC Conjugates | IAPP, IDE, INSR | SMN1; SMN2 2567/4885ALDH1A1 4710/4885FOLH1 1170/4885 |
| US-11471537-B2 | Oligomer extended insulin-Fc conjugates | IAPP, IDE, INSR | SMN1; SMN2 2567/4885ALDH1A1 4710/4885FOLH1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.